Hôpital d'Instruction des Armées Sainte-Anne, Service de Neurologie, 83800 Toulon Cedex 09, France.
Hôpital d'Instruction des Armées Laveran, Service de Neurologie, 83800 Toulon Cedex 09, France; Ecole du Val-de-Grâce, 74, Boulevard de Port-Royal, 75005 Paris, France.
Rev Neurol (Paris). 2018 Mar;174(3):125-136. doi: 10.1016/j.neurol.2017.06.025. Epub 2017 Nov 8.
Intravenous thrombolysis with rt-PA is the key treatment for acute ischemic stroke (IS), and has largely been developed at the Military Teaching Hospital in Toulon since 2003. This report is of the results of our practices compared with those in the literature, as well as our attempts to identify factors predictive of a favorable outcome after thrombolysis.
All patients treated with rt-PA for IS in the carotid territory between 2003 and 2014 were prospectively included. Disability was assessed at 3 months by modified Rankin Scale (m-RS) scores; outcome was considered unfavorable if the m-RS score was >2. Multivariate analyses were also performed to identify parameters correlating with poor and favorable outcomes.
Of the 289 patients prospectively enrolled in the study [mean initial National Institutes of Health Stroke Scale (NIHSS) score: 14.3], 52.5% had an m-RS score >2 at 3 months of follow-up. Three independent predictive factors for poor functional outcomes at the 3-month follow-up were identified: NIHSS score>12 on admission (P=0.048); NIHSS score>8 at discharge (P<0.001); and early neurological worsening within the first 24h (P=0.015). Early neurological improvement within 24h of rt-PA infusion was significantly associated with recanalization of the stroke-related occluded cerebral artery (P<0.001, r=0.37).
After 12 years of practice, our stroke unit has produced results similar to those of the major clinical studies in terms of safety and efficacy. High NIHSS scores on admission and a lack of neurological improvement during the first 24h of thrombolysis due to failure of early recanalization were identified as independent predictive factors of poor functional outcomes.
阿替普酶静脉溶栓是治疗急性缺血性脑卒中(IS)的关键治疗方法,自 2003 年以来,主要在土伦教学医院开展。本报告比较了我们的实践结果与文献结果,并尝试确定溶栓后预后良好的预测因素。
前瞻性纳入 2003 年至 2014 年颈动脉区域内接受阿替普酶治疗的所有 IS 患者。采用改良Rankin 量表(m-RS)评分在 3 个月时评估残疾程度;m-RS 评分>2 被认为预后不良。还进行了多变量分析,以确定与不良和良好结局相关的参数。
在 289 例前瞻性纳入研究的患者中[初始 NIHSS 评分的平均值为 14.3],52.5%在 3 个月的随访时 m-RS 评分>2。在 3 个月的随访时,发现 3 个与不良功能结局相关的独立预测因素:入院时 NIHSS 评分>12(P=0.048);出院时 NIHSS 评分>8(P<0.001);以及发病后 24 小时内的早期神经恶化(P=0.015)。阿替普酶输注后 24 小时内的早期神经改善与脑卒中相关闭塞脑血管再通显著相关(P<0.001,r=0.37)。
在 12 年的实践之后,我们的卒中单元在安全性和疗效方面与主要的临床研究结果相似。入院时 NIHSS 评分较高和溶栓后 24 小时内神经功能无改善,提示早期再通失败,是不良功能结局的独立预测因素。